Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION phase 3 study of givosiran in acute hepatic porphyrias
NL-OMON50649Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of givosiran in acute porphyria and acute intermittent porphyria (AIP) (3 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Annualized rate of porphyria attacks requiring hospitalization, urgent healthcare visit, or home hemin administration. Started Jul 2018; status: completed.
02
Drugs
givosiran
03
Conditions
acute porphyriaacute intermittent porphyria (AIP)
Beyond the preview
Go deeper on NL-OMON50649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50649.